Parkinson’s disease remains one of the most pressing challenges in neurology, with prevalence rising globally and an urgent need for biomarkers that can detect disease early and track progression over time.
The hallmark pathology of Parkinson’s disease includes abnormal aggregation of alpha-synuclein and degeneration of dopaminergic neurons in the substantia nigra pars compacta. Neuromelanin, a dark pigment found in catecholaminergic neurons, provides an imaging handle on this degeneration because its signal in the substantia nigra decreases as these neurons are lost.
Neuromelanin-sensitive MRI reveals the substantia nigra as a bright band in healthy individuals, with clear reductions in both signal intensity and volume in Parkinson’s patients. Even on visual read, radiologists can distinguish Parkinson’s disease patients from controls with approximately 80–85% accuracy, underscoring its potential as a clinically relevant biomarker.
One of the most compelling aspects of neuromelanin MRI is its temporal profile. Studies show that neuromelanin signal and volume decline over the course of Parkinson’s disease, from early to advanced stages, demonstrating its value as a longitudinal marker of progression.
Crucially, neuromelanin changes are detectable in prodromal conditions such as isolated REM sleep behaviour disorder and even in asymptomatic mutation carriers, where volumes sit between those of healthy controls and manifest Parkinson’s disease. By modelling neuromelanin changes over disease duration, researchers estimate that measurable alterations in the substantia nigra emerge around five to six years before the onset of motor symptoms, with around 23% reduction in signal and volume at that point.
Independent cohorts have reproduced these timelines, strengthening confidence that neuromelanin-sensitive MRI captures early neurodegenerative processes that precede clinical diagnosis. Beyond timing, neuromelanin imaging correlates with multiple dimensions of disease burden. Signal changes in different nigral sub-regions relate to motor severity, cognitive scores and behavioural scales, while also aligning with striatal dopamine transporter binding and polygenic risk scores.Together, these findings position neuromelanin MRI as a biomarker that is early, longitudinal and clinically meaningful.
MRI - a practical platform for Parkinson’s trials
MRI offers several inherent advantages as a platform for neuromelanin biomarkers. It is non-invasive and widely available worldwide, making it suitable for large, longitudinal clinical trials. Its multimodal capabilities allow high-resolution imaging of brain structures based on different tissue properties, which is critical when targeting tiny deep-brain nuclei such as the substantia nigra and locus coeruleus. Standard structural MRI sequences, however, are not sufficient: the substantia nigra may be virtually invisible in routine images. Neuromelanin-sensitive techniques overcome this limitation by exploiting differences in T1 relaxation and magnetisation transfer properties between neuromelanin-rich tissue and surrounding regions, enabling these structures to be visualised clearly. In practice, acquisition times are clinically manageable. Research protocols have historically used longer sequences with multiple repeats, but with modern denoising and optimisation, neuromelanin sequences of approximately five minutes are now being deployed in clinical settings.
Looking ahead
For disease-modifying Parkinson’s trials, neuromelanin-sensitive MRI offers a compelling combination: early detectability, longitudinal tracking, correlation with clinical features and mechanistic links to dopaminergic and iron-related pathology. However, important work remains to validate this biomarker on large multi-centre datasets, refine sensitivity and specificity, and optimise standardised protocols and AI-enabled analysis pipelines.
As the field moves forward, neuromelanin-sensitive imaging could play a pivotal role in accelerating the development and evaluation of therapies designed to slow or halt neurodegeneration in Parkinson’s disease. Built by neuroscientists for neuroscience, IXICO’s imaging platform helps turn complex data into clinically meaningful insights. If you would like to explore how advanced imaging could support your clinical development programme, please get in touch.
